FIVE PRIME THERAPEUTICS INC (32)

Browse by Contract Category

Contracts

Form of Gross-Up Agreement (Filed With SEC on April 16, 2021)
Agreement and Plan of Merger, dated as of March 4, 2021, by and among Amgen Inc., Franklin Acquisition Sub, Inc. and Five Prime Therapeutics, Inc (Filed With SEC on March 4, 2021)
Underwriting Agreement, dated November 12, 2020, by and among the Company, Cowen and Company, LLC and SVB Leerink LLC (Filed With SEC on November 13, 2020)
Sublease by and between the company and Sutro Biopharma, Inc., dated as of September 3, 2020 (Filed With SEC on November 3, 2020)
Sales Agreement by and between the Company and Cowen and Company, LLC, dated as of August 6, 2020 (Filed With SEC on August 6, 2020)
Non-Employee Director Compensation Policy, effective November 21, 2019 (Filed With SEC on February 27, 2020)
Amendment No. 4 to the Non-Exclusive License Agreement by and among the company, BioWa, Inc. and Lonza Sales AG, dated as of August 22, 2019 (Filed With SEC on November 6, 2019)
Amendment to Offer Letter Agreement by and between the company and William R. Ringo, dated as of April 16, 2020 (Filed With SEC on August 6, 2020)
Offer Letter Agreement by and between the company and Thomas Civik, dated as of April 6, 2020 (Filed With SEC on August 6, 2020)
Letter Agreement by and between the company and William R. Ringo, dated as of March 6, 2020 (Filed With SEC on May 7, 2020)
Letter Agreement by and between the company and David V. Smith, dated as of December 12, 2019 (Filed With SEC on February 27, 2020)
Executive Severance Benefit Plan and Summary Plan Description, effective November 20, 2019 (Filed With SEC on February 27, 2020)
Letter Agreement by and between the company and Helen Collins, dated as of December 12, 2019 (Filed With SEC on February 27, 2020)
Retention Letter Agreement by and between the company and Francis Sarena, dated as of January 15, 2020 (Filed With SEC on February 27, 2020)
Retention Letter Agreement by and between the company and Helen Collins, dated as of January 15, 2020 (Filed With SEC on February 27, 2020)
Retention Letter Agreement by and between the company and David V. Smith, dated as of January 15, 2020 (Filed With SEC on February 27, 2020)
Letter Agreement by and between the company and Francis Sarena, dated as of December 12, 2019 (Filed With SEC on February 27, 2020)
Amendment to Offer Letter Agreement by and between the company and William R. Ringo, dated as of December 20, 2019 (Filed With SEC on February 27, 2020)
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 27, 2020)
Amendment to Offer Letter Agreement by and between the company and William R. Ringo, dated as of October 8, 2019 (Filed With SEC on November 6, 2019)
Offer Letter Agreement by and between the company and William R. Ringo, dated as of October 4, 2019 (Filed With SEC on November 6, 2019)
Separation Agreement by and between the company and Aron M. Knickerbocker, dated as of September 19, 2019 (Filed With SEC on November 6, 2019)
Amendment No. 3 to the Non-Exclusive License Agreement by and among the company, BioWa, Inc. and Lonza Sales AG, dated as of July 17, 2019 (Filed With SEC on November 6, 2019)
Consulting Agreement by and between the company and Lewis T. Williams, effective as of April 1, 2019 (Filed With SEC on May 9, 2019)
Offer Letter Agreement by and between the company and David V. Smith, dated as of October 24, 2018 (Filed With SEC on February 26, 2019)
Amendment No. 1 to the License and Collaboration Agreement by and between the company and Zai Lab (Shanghai) Co., Ltd., dated as of December 21, 2018 (Filed With SEC on February 26, 2019)
Amendment No. 2 to the Non-Exclusive License Agreement by and among the company, BioWa, Inc. and Lonza Sales AG, dated as of April 27, 2018 (Filed With SEC on February 26, 2019)
Amendment No. 1 to the Non-Exclusive License Agreement by and among the company, BioWa, Inc. and Lonza Sales AG, dated as of June 6, 2013 (Filed With SEC on February 26, 2019)
Amendment No. 1 to the Confidential Consulting Agreement by and between the company and FLG Partners, LLC, dated as of October 13, 2018.v (Filed With SEC on February 26, 2019)
Executive Severance Benefits Agreement by and between the company and David V. Smith, dated as of November 26, 2018 (Filed With SEC on February 26, 2019)
Executive Severance Benefits Agreement by and between the company and Bryan Irving, dated as of September 5, 2017 (Filed With SEC on February 26, 2019)
Offer Letter Agreement by and between the company and Bryan Irving, dated as of July 27, 2017 (Filed With SEC on February 26, 2019)